

2021 Fourth Quarter Financial and Corporate Update -

.

100

1270

ED (23

1

100

-

Forward-Looking Statements

Except for the historical information set forth herein, the matters set forth in this presentation contain predictions, estimates and other forward-looking statements, including statements regarding: the opportunities for growth and diversification presented by Incyte's portfolio; our and our collaborators' potential for receiving regulatory approvals within the next 1-2 years and the corresponding potential for launches of new products and/or indications; our expectations for sales of our products and the guidance provided regarding the same; expectations with respect to demand for and uptake of Opzelura; our ongoing discussions with GPOs/PBMs regarding Opzelura; the opportunity presented by ruxolitinib cream to treat patients with vitiligo and the timing of regulatory review for submissions regarding the same; our expanding dermatology pipeline; expectations regarding the initiation or completion of other clinical trials for various of our product candidates; our 2022 GAAP and Non-GAAP financial guidance and expectations underlying that guidance; and our expectations regarding 2022 newsflow items.

These forward-looking statements are based on our current expectations and are subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: the actual time required by the regulatory authorities to review submissions for regulatory approval and the results of such reviews; unanticipated delays, including unanticipated delays in the Company's submissions seeking regulatory approval; the effects of the COVID-19 pandemic and measures to address the pandemic on the Company's clinical trials, supply chain and other third-party providers, sales and marketing efforts and business, development and discovery operations as well as on regulatory agencies such as the FDA; further research and development; the ability to enroll sufficient numbers of subjects in clinical trials and the ability to enroll subjects in accordance with planned schedules; determinations made by the FDA, EMA and other regulatory agencies; our dependence on relationships with and changes in the plans and expenditures of our collaboration partners; the efficacy or safety of our products and the products of our collaboration partners; the effects of announced or unexpected price regulation or limitations on reimbursement or coverage for our products and the products of our collaboration partners; sales, marketing, manufacturing and distribution requirements, including our and our collaboration partners' ability to successfully commercial infrastructure for newly approved products and any additional new products that become approved; greater than expected expenses, including expenses, relating to litigation or strategic activities; and other risks detailed from time to time in the Company's reports filed with the Securities and Exchange Commission.



FOURTH QUARTER REVIEW

HERVÉ HOPPENOT – CEO



63


100

1

I NOT

150

Continued Revenue Growth and Diversification





Jakavi (ruxolitinib) licensed to Novartis ex-US, Tabrecta (capmatinib) licensed to Novartis worldwide, Olumiant (baricitinib) licensed to Lilly worldwide; these brands are registered trademarks of Novartis (Jakavi and Tabrecta) and Lilly (Olumiant). Iclusig (ponatinib) is a registered trademark of ARIAD. Monjuvi (tafasitamab-cxix) is a registered trademark of MorphoSys.


1. Monjuvi revenues recognized by MorphoSys and included in our collaboration loss sharing line item on our condensed consolidated statement of operations in our fourth quarter and full year 2021 financial results press release issued on February 8, 2022.

2. Totals may not add due to rounding.



Multiple Growth Opportunities Across Our Portfolio

New Launches in Growth Phase



Upcoming Regulatory Decisions

- **Ruxolitinib cream** under review in U.S. and EU for vitiligo
- Ruxolitinib under review in EU and Japan for GVHD
- **Capmatinib** under review in EU for NSCLC
- Baricitinib regulatory applications submitted in U.S., EU and Japan for AA




Iclusig (ponatinib) is a registered trademark of ARIAD. Monjuvi (tafasitamab-cxix) is a registered trademark of MorphoSys. DLBCL=diffuse large b-cell lymphoma; GVHD=graft-versus-host disease; NSCLC = non-small cell lung cancer; AA = alopecia areata; MF=myelofibrosis; PV=polycythemia vera; CCA=cholangiocarcinoma; BTC=biliary tract carcinoma; CML=chronic myeloid leukemia; AD = atopic dermatitis

- 1. Pemazyre is approved for cholangiocarcinoma in the U.S. and in Europe and is approved in Japan for biliary tract cancer
- 2. Monjuvi revenues recognized by MorphoSys and included in our collaboration loss sharing line item on our condensed consolidated statement of operations in our fourth quarter 2021 financial results

Peak Sales Guidance

	MPN/GVHD franchise	MF, PV, GVHD	\$3+ Billion U.S.
Onc	tafasitamab-cxix 20mg terejector, teristravenous use	2L DLBCL	\$500 - \$750 Million ² U.S.
Heme/Onc	tafasitamab	2L DLBCL	N/A
Ĭ	pemazyre (pemigatinib)	CCA/BTC ²	N/A
	(ponatinib) tablets	CML	N/A
Dermatology	Opzelura " (ruxolitinib) cream 1.5%	AD	\$1.5+ Billion U.S.

Building a Portfolio in Dermatology





U.S. COMMERCIAL UPDATE

BARRY FLANNELLY – GENERAL MANAGER, NORTH AMERICA




1

63

.....

Strong Performance During Launch of Opzelura



*Holiday week

Incyte

NBRx = new-to-brand prescription

1. 867 Product Transfer and Resale Data, 2/3/2022

2. IQVIA data week ending 1/28/2022


3. Dupixent excludes scripts written by Pulmonologists, Otolaryngologists, and portion of scripts written by Allergists

Positive HCP Feedback after Prescribing Opzelura Mean Number of Initiations of Opzelura¹ **Survey Results Top Drivers of Prescribing²** In the PAST MONTH, to how many atopic dermatitis patients did you prescribe **Opzelura for the first time? (n=41)** Efficacy In the NEXT MONTH, to how many atopic dermatitis patients do you expect to prescribe Opzelura for the first time? (n=43) Rapid onset of action \succ Itch reduction 6.9 \succ Skin clearance Safe topical treatment \checkmark 3.7 Use in sensitive areas \checkmark Non-steroidal option \checkmark Novel mechanism of action

Initiated in past month


Will initiate in next month





Expect Shift from Early Launch Patient Support Programs

- Utilization of patient program to cover full cost of Opzelura to decline as product is added to formularies
- Co-pay mitigation to lower a patient's out-of-pocket cost to as little as \$10






Jakafi Growth Driven by New Patient Starts



Q4'21 sales \$592m (+15% Y/Y) FY21 sales \$2.1b (+10% Y/Y)

Strong patient demand across all indications in FY'21

- New patient starts in 2021 grew 16% Y/Y (+13% vs 2019)
- Successful launch in chronic GVHD in Q4'21
 - ➢ GVHD new patient growth of 39% Y/Y in Q4′21




FY'22 guidance of \$2.3 to \$2.4 billion

- Continued recovery of new patient starts
- Ongoing launch in chronic GVHD




Jakafi (ruxolitinib) is approved by the FDA for treatment of adults with intermediate or high-risk myelofibrosis, for treatment of adults with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea and for the treatment of steroid-refractory acute GVHD and steroid-refractory chronic GVHD in adult and pediatric patients 12 years and older.


1. Patient growth rates refer to total number of patients on therapy during FY'21 vs FY'20.



Monjuvi and Pemazyre Uptake Continues to Grow




- Increasing Monjuvi usage in the 2L setting
- Minjuvi launch ongoing in Germany





Q4'21 sales \$20m (+40% Y/Y) FY'21 sales \$69m (+165% Y/Y)

- Majority of patients initiating therapy in the 2L setting
- Duration of therapy continues to drive performance





tafasitamab

Development and U.S. commercialization of tafasitamab in collaboration with MorphoSys. Monjuvi (tafasitamab-cxix) is a CD19-directed cytolytic antibody indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT). 1. Monjuvi revenues recognized by MorphoSys and included in our collaboration loss sharing line item on our condensed consolidated statement of operations in our fourth quarter 2021 financial results press release issued on Feb 8, 2022.

CLINICAL DEVELOPMENT

STEVEN STEIN – CHIEF MEDICAL OFFICER



1

0

(11) (11)


 150

1

63

......

Clinical and Regulatory Achievements in 2021






JAKi = Jak-inhibitor; AD = atopic dermatitis; GVHD = graft-versus-host disease; DLBCL = diffuse-large B-cell lymphoma; CCA = cholangiocarcinoma; BTC = biliary tract cancer; wAIHA = warm autoimmune hemolytic anemia; NSCLC = nonsmall cell lung cancer

I. Development of axatilimab in collaboration with Syndax Pharmaceuticals

Priority Review for Ruxolitinib Cream in Vitiligo (PDUFA 4/18)





Advancing Multiple Programs in Dermatology

	Ruxolitinib Cream				INCB54707			
Indication	Atopic Dermatitis	Chronic Hand Eczema	Vitiligo		Hidradenitis Suppurativa	Prurigo Nodularis		
Patients	Pediatric	Moderate /Severe	BSA≤10% BSA≥8%		Draining fistula count <u><</u> 20	≥ 20 nodules		
Clinical Trials	 TRuE-AD3 Max Use (>2 to <12) 	TRuE-CHE1	 TRuE-V1 Phase 2 TRuE-V2 		Phase 2	Phase 2		
Data in 2022			PDUFA Apr 18 H2'22		H2′22			
Epidemiology in the U.S.	2-3 Million pediatric patients ¹	4% of population ²	>1.5 Million ³		>1.5 Million ³		0.1% ⁴ of population	>200,0005

1. DRG; Silverberg JI. Dermatol Clin. 2017;35(3):283-289

2. Quaade AS, Simonsen AB, Halling AS, Thyssen JP, Johansen JD. Prevalence, incidence, and severity of hand eczema in the general population - A systematic review and meta-analysis. Contact Dermatitis. 2021 Jun;84(6):361-374. doi: 10.1111/cod.13804. Epub 2021 Feb 23. PMID: 33548072.

3. Bergqvist C, Ezzedine K. Vitiligo: A Review. Dermatology 2020;236:571-592. doi: 10.1159/000506103

4. Garg A, Kirby JS, Lavian J, Lin G, Strunk A. Sex- and Age-Adjusted Population Analysis of Prevalence Estimates for Hidradenitis Suppurativa in the United States. JAMA Dermatol. 2017 Aug 1;153(8):760-764. doi: 10.1001/jamadermatol.2017.0201. PMID: 28492923; PMCID: PMC5710402.

5. https://www.uptodate.com/contents/prurigo-nodularis

Incyte

LIMBER: Opportunities for Continued Growth in MPNs/GVHD

Formulation –	MF, PV, GVHD	
Asset	Status	Submission
QD Ruxolitinib	Stability Testing	H1 2022

Myelofibrosis		
Asset	Status	Upcoming Data
parsaclisib + ruxolitinib	 Phase 3 inadequate responders Phase 3 1st line 	Top-line results in 2023 (inadequate responder)
BET + ruxolitinib	PoC	Initial data in 2022
ALK2 + ruxolitinib	PoC	Initial data in 2022
CK0804 ¹ (Cellenkos)	PoC	
Novel Targets	Preclinical	

Polycythemia vera							
Asset	Status	Upcoming Data					
Novel Targets	lovel Targets Preclinical						
Graft-versus-host disease							
Asset	Status	Upcoming Data					
itacitinib	Dose-ranging (SN cGVHD)	Part 1 data in 2022					
axatilimab	Pivotal Phase 2 (3 rd line plus cGVHD)	Top-line results in 2023					



1. Development of CK0804 plus ruxolitinib in collaboration with Cellenkos.

2. Development of axatilimab in collaboration with Syndax Pharmaceuticals.

Other Development Highlights

Tafasitamab				Early Hemato	ogy/Oncology
Indication	Status	Upcoming Data		Asset	Status
1L DLBCL	Phase 3 (<i>frontMIND</i>)	Top-line results in 2025	(Oral PD-L1	
Other r/r NHL	PoC (<i>topMIND</i>) Phase 3 (<i>inMIND</i>)	Top-line results in 2023 Top-line results in 2023 ¹		INCB86550	Phase 2 (enrolling); dose schedule optimization
				INCB99280	Dose escalation
				INCB99318	Dose escalation
				Adenosine	
Parsaclisib				INCB106385 (A ₂ A/A ₂ B)	Phase 1: mono or combo with PD-1
Indication	Status	Upcoming Data		INCA00186	Phase 1: mono or
Warm Autoimmune Hemolytic Anemia	Phase 3 initiated			(CD73)	combo with PD-1 and/o A_2A/A_2B

Early Hematology/Oncology							
Asset	Status	Upcoming Data					
Oral PD-L1							
INCB86550	Phase 2 (enrolling); dose schedule optimization	 Selection of lead program(s) in 2022 					
INCB99280	Dose escalation	 Indications for development based on 					
INCB99318	Dose escalation	clinical profile					
Adenosine							
INCB106385 (A ₂ A/A ₂ B)	Phase 1: mono or combo with PD-1	2022					
INCA00186 (CD73)	Phase 1: mono or combo with PD-1 and/or A_2A/A_2B	2022					
LAG-3 + TIM-3 with a	nd without PD-1						
INCAGN2385	Phase 1/2						



DLBCL = diffuse-large B-cell lymphoma; NHL= non-Hodgkin's lymphoma; PoC= proof-of-concept

1. Incyte's February 8, 2022 Fourth Quarter Financial and Corporate Update presentation originally stated top-line results in 2024 in error. A corrected version of this presentation now appears on Incyte's website.

1H 2022

			NDA submission					
	QD ruxolitinib	MF, PV, GVHD	NDA SUDMISSION				-	
DHV	BET + ruxolitinib	myelofibrosis			Initial data			•
MPNs/GVHD	ALK2 + ruxolitinib	myelofibrosis			Initial data			
Σ	itacitinib	GVHD			Results from Part 1 (dose-finding)			1
Ap Vp	Oral PD-L1	solid tumors			Lead program selection		12	
Other Hematology / Oncology	A_2A/A_2B	solid tumors			Initial data			
Hen / 0	CD73	solid tumors			Initial data		J,	
	ruxolitinib cream	vitiligo	FDA decision (PDUFA Apr 18)		EMA decision			
tology	ruxolitinib cream	chronic hand eczema	Phase 3 initiation					
Dermatology	INCB54707	vitiligo			Phase 2 data			
	INCB54707	hidradenitis suppurativa			Phase 2 data			
ي ب	ruxolitinib	acute & chronic GVHD	EMA and	PMDA	decision			
Royalties	capmatinib	NSCLC	EM	A decis	ion			
Ro	baricitinib	alopecia areata	FDA, EMA a	nd PMI	DA decision			



FINANCIAL RESULTS

CHRISTIANA STAMOULIS – CFO



1

0

-

(10) (10)

 150

1

63

......

Non-GAAP Adjustments


- Management has chosen to present financial highlights for the quarter and year ended December 31, 2021 and 2020 on both a GAAP and Non-GAAP basis in the belief that this Non-GAAP information is useful for investors.
- Management uses such information internally and externally for establishing budgets, operating goals and financial planning purposes. These metrics are also used to manage the Company's business and monitor performance. The Company adjusts, where appropriate, for expenses in order to reflect the Company's core operations.
- The Company believes these adjustments are useful to investors by providing an enhanced understanding
 of the financial performance of the Company's core operations. The metrics have been adopted to align the
 Company with disclosures provided by industry peers.





Financial Highlights: Product & Royalty Revenue


\$ millions	Q4 2021 GAAP	Q4 2020 GAAP	YoY Change	FY 2021 GAAP	FY 2020 GAAP	YoY Change
Net product revenues	648	559	16%	2,322	2,069	<i>12%</i>
Jakafi	592	517	15%	2,135	1,938	10%
Other Hematology/Oncology ¹	51	43	20%	183	131	40%
Opzelura	5	-	NM	5	-	NM
Royalties	165	120	37%	569	393	45%
Jakavi	96	87	10%	338	278	22%
Olumiant	66	31	113%	221	111	99%
Tabrecta	3	2	56%	10	4	151%
Total product and royalty revenues	813	680	20%	2,891	2,462	17%





Totals may not add due to rounding. For all periods there were no adjustments between GAAP and Non-GAAP revenues. 1. Pemazyre in the U.S., EU and Japan and Iclusig and Minjuvi in the EU.

Q4'21 Opzelura Gross-to-Net Sales Reconciliation





Financial Highlights: Operating Expenses

\$ millions	Q4 2021 GAAP	Q4 2020 GAAP	YoY Change	FY 2021 GAAP	FY 2020 GAAP	YoY Change
COGS	44	36	21%	151	131	15%
As a percentage of net product revenues	7%	6%		7%	6%	
R&D	473 ²	406	16%	1,458 ²	2,216 ¹	-34%
R&D – ongoing	345	380	-9%	1,309	1,240	6%
R&D – upfront and milestones	128 ²	26	392%	149 ²	976 ¹	-85%
SG&A	226	167	35%	740	517	43%
Collaboration loss sharing ³	8	12	-39%	37	43	-14%



Totals may not add due to rounding.


Incyte

1. Includes upfront consideration of \$805 million related to our collaborative agreement with MorphoSys and \$120 million of expense related to the purchase of an FDA priority review voucher.

2. Includes upfront consideration of \$127 million related to our collaborative agreement with Syndax.

3. Incyte's 50% share of the U.S. net commercialization loss for Monjuvi under our collaboration agreement with MorphoSys.

Operating Leverage



Incyte

Chart shows Product & royalty revenue and GAAP ongoing R&D expense (excluding upfront and milestones) plus GAAP SG&A expense for FY 2016 - FY 2021.

1. Compound annual growth rate 2018 – 2021.


Financial Guidance: Full Year 2022

	FY 2022 GAAP	FY 2022 Non-GAAP ²
Net product revenues		
Jakafi	\$2.3 – \$2.4 billion	\$2.3 – \$2.4 billion
Other Hematology/Oncology 1	\$210 – \$240 million	\$210 – \$240 million
Costs and expenses		
COGS	6 – 7% net product revenues	5 – 6% net product revenues
R&D	\$1,550 – \$1,590 million	\$1,420 – \$1,455 million
SG&A	\$950 - \$1,000 million	\$880 - \$925 million



1. Pemazyre in the U.S., EU and Japan and Iclusig and Minjuvi in the EU.

2. A reconciliation from GAAP to Non-GAAP financial measures is provided on slide 33.



1H 2022

	QD ruxolitinib	MF, PV, GVHD	NDA submission			. '	۰.		
QHV	BET + ruxolitinib	myelofibrosis			Initial data				
MPNs/GVHD	ALK2 + ruxolitinib	myelofibrosis			Initial data				
Σ	itacitinib	GVHD			Results from Part 1 (dose-finding)				1
ABO	Oral PD-L1	solid tumors			Lead program selection			1	
Other Hematology	A ₂ A/A ₂ B	solid tumors			Initial data				
Her -	CD73	solid tumors			Initial data				
	ruxolitinib cream	vitiligo	FDA decision (PDUFA Apr 18)		EMA decision				
Dermatology	ruxolitinib cream	chronic hand eczema	Phase 3 initiation						
Derma	INCB54707	vitiligo			Phase 2 data				
	INCB54707	hidradenitis suppurativa			Phase 2 data				
S	ruxolitinib	acute & chronic GVHD	EMA and PMDA decision						
Royalties	capmatinib	NSCLC	EMA decision						
R	baricitinib	alopecia areata	FDA, EMA and PMDA decision						



FINANCIAL BACK-UP SLIDES



(11) (11)

 .

Financial Highlights: Q4

	Q4 2021	Q4 2020	Q4 2021	Q4 2020
\$ millions	GAAP	GAAP	Non-GAAP	Non-GAAP
Net product revenues	648	559	648	559
Jakafi	592	517	592	517
Iclusig	27	29	27	29
Pemazyre	20	14	20	14
Minjuvi	4	-	4	-
Opzelura	5	-	5	-
Royalties	165	120	165	120
Jakavi	96	87	96	87
Olumiant	66	31	66	31
Tabrecta	3	2	3	2
Total product and royalty revenues	813	680	813	680
Milestones and contract revenues	50	110	50	110
Total revenues	863	790	863	790
Costs and expenses	752	625	697	571
COGS ¹	44	36	38	31
R&D ²	473	406	443	376
$R\&D - ongoing^2$	345	380	315	350
% total revenues	40%	48%	36%	44%
R&D – upfront and milestones	128	26	128	26
SG&A ³	226	167	209	152
% total revenues	26%	21%	24%	19%
Contingent consideration ⁴	2	4	-	-
Collaboration loss sharing	8	12	8	12



Totals may not add due to rounding.

Non-GAAP excludes \$5.4 million of amortization of acquired product rights for Q4 2021 and 2020 and \$0.6 million and \$0.2 million of stock compensation for Q4 2021 and 2020, respectively.
 Non-GAAP excludes \$30.1 million and \$30.2 million of stock-based compensation for Q4 2021 and 2020, respectively.

3. Non-GAAP excludes \$17.5 million and \$14.8 million of stock-based compensation for Q4 2021 and 2020, respectively.

4. Non-GAAP excludes \$1.7 million and \$3.6 million of change in fair value of contingent consideration for Q4 2021 and 2020, respectively.

Financial Highlights: Year-to-Date

\$ millions	YTD 2021	YTD 2020	YTD 2021	YTD 2020
	GAAP	GAAP	Non-GAAP	Non-GAAP
Net product revenues	2,322	2,069	2,322	2,069
Jakafi	2,135	1,938	2,135	1,938
Iclusig	109	105	109	105
Pemazyre	69	26	69	26
Minjuvi	5	-	5	-
Opzelura	5	-	5	-
Royalties	569	393	569	393
Jakavi	338	278	338	278
Olumiant	221	111	221	111
Tabrecta	10	4	10	4
Total product and royalty revenues	2,891	2,462	2,891	2,462
Milestones and contract revenue	95	205	95	205
Total revenues	2,986	2,667	2,986	2,667
Costs and expenses	2,400	2,930	2,161	2,708
COGS ¹	151	131	128	109
R&D ²	1,458	2,216	1,344	2,096
$R\&D - ongoing^2$	1,309	1,240	1,195	1,120
% total revenues	, 44%	46%	, 40%	, 42%
R&D – upfront and milestones	149	976	149	976
SG&A ³	740	517	653	460
% total revenues	25%	19%	22%	17%
Contingent consideration ⁴	15	23	-	-
Collaboration loss sharing	37	43	37	43

Incyte

Totals may not add due to rounding.

1. Non-GAAP excludes \$21.5 million of amortization of acquired product rights for YTD 2021 and 2020 and \$1.7 million and \$1.0 million of stock compensation for YTD 2021 and YTD 2020, respectively.

2. Non-GAAP excludes \$114.3 million and \$120.4 million of stock-based compensation for YTD 2021 and YTD 2020, respectively.

3. Non-GAAP excludes \$20.0 million of legal settlements for YTD 2021 and \$67.0 million and \$56.6 million of stock-based compensation for YTD 2021 and YTD 2020, respectively.

4. Non-GAAP excludes \$14.7 million and \$23.4 million of change in fair value of contingent consideration for YTD 2021 and YTD 2020, respectively.

2022 Financial Guidance Non-GAAP Reconciliation

	GAAP Guidance	Adjustments	Non-GAAP Guidance
Net product revenues			
Jakafi	\$2.3 – \$2.4 billion	-	\$2.3 – \$2.4 billion
Other Hematology/Oncology ¹	\$210 – \$240 million	-	\$210 – \$240 million
Costs and expenses			
COGS	6 – 7% net product revenues	Amortization of acquired product rights for Iclusig and stock-based compensation	5 – 6% net product revenues
R&D	\$1,550 – \$1,590 million	Stock-based compensation (\$130 - \$135 million)	\$1,420 – \$1,455 million
SG&A	\$950 – \$1,000 million	Stock-based compensation (\$70 - \$75 million)	\$880 – \$925 million

